Breast cancer drug gets FDA approval
(Reuters) - U.S. health regulators have approved a new breast cancer drug from pharmaceutical company Roche that the company hopes will become the standard treatment for women with an aggressive form of cancer.
Roche unit Genentech announced Friday that the Food and Drug Administration approved the injectable drug Perjeta for women with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers.
The FDA accepted the application for the drug under priority review, meaning the agency believes the drug may represent a potentially significant advancement over existing treatments. In clinical trials, the drug kept women's cancer from worsening for six extra months, compared to the current standard of care.
Breast cancer, the most common cancer among women worldwide, will afflict about 227,000 U.S. women in 2012, and kill about 39,500 of them, according to the American Cancer Society.
Genentech, which developed Perjeta, suffered a blow last year when the FDA revoked approval for its blockbuster drug Avastin as a treatment for breast cancer, saying the drug was not effective enough to justify its risks.
At the time, FDA advisers and other experts said Genentech should have done more trials to see exactly which subset of breast cancer patients would most benefit from the treatment.
Roche said Perjeta, known generically as pertuzumab, would only be available for women who are diagnosed with the HER2-positive form of breast cancer.
Like other biotech drug makers, Roche is seeking to extend the longevity of its expensive brand-name medicines. Perjeta is part of that strategy, as it is a follow-on version of Herceptin, a breakthrough breast cancer drug that is the company's third-largest seller.
Both Herceptin, first approved in 1998, and pertuzumab are antibodies designed to block the function of HER2, a protein produced by a cancer-linked gene. Pertuzumab binds to a different part of the same protein, which the company says makes the drug combination extra effective.
In clinical trials, women who took Perjeta in addition to Herceptin and chemotherapy had 18.5 months without their tumors growing, compared to 12.4 months for those who just took the older drugs.
Genentech is also testing Perjeta as a treatment for early-stage and advanced HER2-positive breast cancer and advanced HER2-positive stomach cancer.
The company is also developing an "armed antibody" known as TDM-1 as a treatment for HER2-positive breast cancer. TDM-1 combines Herceptin with a derivative of a powerful type of chemotherapy.
Sign Up for Free Newsletters
Ask Your Doctor the RIGHT Questions!
the most from your doctor visit.
Emailed right to you!
The Ask Your Doctor email series
may contain sponsored content.
18+, US residents only please.
Get the MOST from QualityHealth
- Top Searches
- 1. Arthritis Management: Nature Heals
- 2. 5 Digestive To-Dos
- 3. Men: Should You Shave It or Leave It?
- 4. Today's Top Fitness Trends
- 5. Sugar and Osteoarthritis : The Link
- 6. Can't Afford Your Hospital Bills?
- 7. Stay Energized All Day Long
- 8. Phobias: Who Has Them and Why?
- 9. What If Your EpiPen Fails?
- 10. 5 Costly Medical Billing Mistakes
- 1. Ice Falls Can Cause Serious Injuries
- 2. Can Inactivity Act Like a Disease?
- 3. Kale Snack Recipe for Diabetics
- 4. How Running Affects Arthritis
- 5. Sugar and Your Immunity System
- 6. Do Weight Loss Supplements Work?
- 7. 5 Super Foods for Spring
- 8. The Hazards of Reusable Bags
- 9. How to Avoid Ingrown Hairs
- 10. Health Tip: Constantly Change Shoes
- 1. 4 Common Treatments for Epilepsy
- 2. What Does a Urogynecologist Do?
- 3. GERD Without Heartburn? It's Possible
- 4. Graston Technique: Can It Work on You?
- 5. Music Therapy Can Help Autism
- 6. 8 Ways to Fight MS-Related Fatigue
- 7. Can You Still Bleed After Menopause?
- 8. Be Your Own Health Care Advocate
- 9. Why Is Syphillis on the Rise?
- 10. Ideal Weight vs. Happy Weight
The material on the QualityHealth Web site is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a physician or other qualified health provider. See additional information.